El-Karaksy Hanaa M, Mohsen Lamiaa M, Saleh Doa'a A, Hamdy Mona S, Yassin Noha A, Farouk Mohamed, Salit Mohamed E, El-Shabrawi Mortada H
Hanaa M El-Karaksy, Lamiaa M Mohsen, Noha A Yassin, Mohamed Farouk, Mortada H El-Shabrawi, Department of Pediatrics, Kasr Al-Ainy School of Medicine, Cairo University, Cairo 11562, Egypt.
World J Gastroenterol. 2014 Dec 7;20(45):17075-83. doi: 10.3748/wjg.v20.i45.17075.
To identify possible maternal risk factors for hepatitis B virus (HBV) acquisition and assess the efficacy of immunoprophylaxis given to infants born to hepatitis B virus surface antigen (HBsAg) positive mothers.
Screening of 2000 pregnant females was carried out using rapid test and confirmed by enzyme immunoassay. A questionnaire consisting of 20 questions about the possible risk factors for acquisition of HBV infection was filled for every pregnant HBsAg positive female in addition to at least 2 pregnant HBsAg negative females for each positive case. Infants of HBsAg positive women were offered passive and active immunoprophylaxis within the 1st 48 h after birth, in addition to 2nd and 3rd doses of HBV vaccine after 1 and 6 mo respectively. Infants were tested for HBsAg and hepatitis B surface antibodies (HBsAb) at six months of age.
HBsAg was confirmed positive in 1.2% of tested pregnant women. Risk factors significantly associated with HBV positivity were; history of injections (OR = 5.65), history of seeking medical advice in a clinic (OR = 7.02), history of hospitalization (OR = 6.82), history of surgery (OR = 4) and family history of hepatitis (OR = 3.89) (P < 0.05). Dropout rate was 28% for HBsAg women whose rapid test was not confirmed and could not be reached to provide immunoprophylaxis for thier newborns. Immunoprophylaxis failure was detected in only one newborn (3.7%) who tested positive for HBsAg at 6 mo of age; and vaccine failure (seronegative to HBsAb after 4 doses of the vaccine) was detected in another one (3.7%). The success rate of the immunoprophylaxis regimen was 92.6%.
This pilot study shows that a successful national program for prevention of perinatal transmission of HBV needs to be preceded by an awareness campaign to avoid a high dropout rate.
确定乙型肝炎病毒(HBV)感染的可能母体危险因素,并评估对乙型肝炎病毒表面抗原(HBsAg)阳性母亲所生婴儿进行免疫预防的效果。
采用快速检测法对2000名孕妇进行筛查,并通过酶免疫测定法进行确认。除了为每例HBsAg阳性孕妇填写一份由20个关于HBV感染可能危险因素的问题组成的问卷外,每例阳性病例还至少为2名HBsAg阴性孕妇填写问卷。HBsAg阳性女性的婴儿在出生后48小时内接受被动和主动免疫预防,此外,分别在1个月和6个月后接种第2剂和第3剂乙肝疫苗。婴儿在6个月大时检测HBsAg和乙肝表面抗体(HBsAb)。
1.2%的受检孕妇HBsAg确诊为阳性。与HBV阳性显著相关的危险因素有:注射史(比值比[OR]=5.65)、在诊所就医史(OR=7.02)、住院史(OR=6.82)、手术史(OR=4)和肝炎家族史(OR=3.89)(P<0.05)。快速检测未得到确认且无法联系到为其新生儿提供免疫预防的HBsAg阳性女性的失访率为28%。仅1名新生儿(3.7%)在6个月大时HBsAg检测呈阳性,检测到免疫预防失败;另1名新生儿(3.7%)检测到疫苗接种失败(4剂疫苗接种后对HBsAb呈血清阴性)。免疫预防方案的成功率为92.6%。
这项初步研究表明,在开展成功的全国性预防HBV围产期传播项目之前,需要开展提高认识活动,以避免高失访率。